Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials

Post-acute (long) COVID-19 quality of life: validation of the German version of (PAC19QoL) instrument

(2023) Srikanth Umakanthan et al.   Frontiers in Public Health

Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study

(2022) Srikanth Umakanthan et al.   POSTGRADUATE MEDICAL JOURNAL

SARS-CoV-2 pathogenesis

(2022) Mart M. Lamers et al.   NATURE REVIEWS MICROBIOLOGY

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

(2022) Dang The Hung et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

(2022) Obbina Abani et al.   LANCET

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis

(2022) Weihao Shao et al.   Emerging Microbes & Infections

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis

(2022) Jerin Jose Cherian et al.   Frontiers in Pharmacology

COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021–2022

(2022) Duncan Chanda et al.   Open Forum Infectious Diseases

Social Environmental Predictors of COVID-19 Vaccine Hesitancy in India: A Population-Based Survey

(2022) Srikanth Umakanthan et al.   Vaccines

Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19

(2022) Hoda Awad et al.   Pharmaceuticals

From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?

(2021) S Rakedzon et al.   JOURNAL OF TRAVEL MEDICINE

CDC Interim Recommendations for Fully Vaccinated People

(2021) Athalia Christie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

(2021) Eduardo López-Medina et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

(2021) Nurullah Okumuş et al.   BMC INFECTIOUS DISEASES

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

(2021) Sylwester Drożdżal et al.   DRUG RESISTANCE UPDATES

COVID-19 Vaccine Hesitancy and Resistance in India Explored through a Population-Based Longitudinal Survey

(2021) Srikanth Umakanthan et al.   Vaccines

Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey

(2021) Jing Hong et al.   Journal of Integrative Medicine-JIM

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Structural basis for RNA replication by the SARS-CoV-2 polymerase

(2020) Quan Wang et al.   CELL

Old and re-purposed drugs for the treatment of COVID-19

(2020) Shio-Shin Jean et al.   Expert Review of Anti-Infective Therapy

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

(2020) Fabrizio Cantini et al.   JOURNAL OF INFECTION

Droplets and Aerosols in the Transmission of SARS-CoV-2

(2020) Matthew Meselson   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir in covid-19

(2020) Robin E Ferner et al.   BMJ-British Medical Journal

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

(2020) Andrey A Ivashchenko et al.   CLINICAL INFECTIOUS DISEASES

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

(2020) Markus Hoffmann et al.   NATURE

A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19

(2020) Yohei Doi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

(2020) Fabio Rocha Formiga et al.   JOURNAL OF CONTROLLED RELEASE

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

(2020) Timothy N. Hoang et al.   CELL

Vaccinating the UK against covid-19

(2020) Azeem Majeed et al.   BMJ-British Medical Journal

BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses

(2019) Audrey Béliveau et al.   BMC Medical Research Methodology

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH